Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets open in red
Thu, 11 Dec 09:30 am

Asian stock markets have opened on a negative note with stock markets in Hong Kong (down 1.2%) and Japan (down 0.9%) leading the losses. Only stock market in Taiwan is trading marginally higher (up 0.04%). The Indian stock markets too have opened the day on a negative note. All the sectoral indices are have opened in red with capital goods and auto stocks witnessing maximum selling pressures.

The Sensex today is down by around 110 points (0.4%), while the NSE-Nifty is down by about 37 points (0.4%). The mid cap and small cap stocks too have also opened in red with BSE Mid Cap index and BSE Small Cap index down by around 0.28% and 0.15% respectively. The rupee is currently trading at Rs 61.95 to the US dollar.

Automobile stocks have opened mixed with Escorts Ltd and TVS motors Ltd leading the gains. However, Tata Motors Ltd and Eicher motors Ltd were facing selling pressure. As per a leading financial daily, Tata Motors is planning to double its dealer network in the country by 2020. To achieve its goal, the company is targeting rural areas and cites alike. The company is looking to increase the market share and dominate the Indian passenger car market. Reportedly, the company, which currently has around 500 touch points currently in India, is aiming to add equal number of dealerships to expand its presence. Currently, company has 15% share in the rural areas and expansion of network will help in increasing this share.

Majority of Indian pharma stocks have opened the day on a negative note, with Natco Ltd and Piramal Enterprise being the leading losers. As per a leading financial daily, drug major Cipla Ltd has announced a sale of its entire 48.22% stake in China-based Jiangsu Cdymax Pharmaceuticals for USD 18.5 million. The company has taken this step to realign its global business. Reportedly, Cipla had acquired stake in this company in order to explore formulations opportunity in China. However, since the company has realigned its global strategy, Cipla did not see strategic fit in holding on the stake. Hence the company has sold its stake. As per the Cipla's spokesperson, the company expects good potential in China pharma market and will be evaluating opportunity going forward.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.